Biotech Analysis Central Pharma News: Novartis’s Gene Therapy Catch, AstraZeneca’s NASH Move, Clovis’s … – Seeking Alpha
|
Biotech Analysis Central Pharma News: Novartis's Gene Therapy Catch, AstraZeneca's NASH Move, Clovis's …
Seeking Alpha The biggest reason for the deal was because of AveXis knowledge in gene therapy. In addition, AveXis's main clinical candidate is AVXS-101 treats spinal muscular atrophy (SMA), which is a rare disease that affects the motor nerve cells in the spinal … |
